CN119948054A - 抗slc34a2单克隆抗体及其用途 - Google Patents

抗slc34a2单克隆抗体及其用途 Download PDF

Info

Publication number
CN119948054A
CN119948054A CN202380053616.2A CN202380053616A CN119948054A CN 119948054 A CN119948054 A CN 119948054A CN 202380053616 A CN202380053616 A CN 202380053616A CN 119948054 A CN119948054 A CN 119948054A
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
antibody
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380053616.2A
Other languages
English (en)
Chinese (zh)
Inventor
李润生
黄文韬
李一帆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Lixin Pharmaceutical R&d Co ltd
Original Assignee
Shanghai Lixin Pharmaceutical R&d Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Lixin Pharmaceutical R&d Co ltd filed Critical Shanghai Lixin Pharmaceutical R&d Co ltd
Publication of CN119948054A publication Critical patent/CN119948054A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202380053616.2A 2022-06-22 2023-06-21 抗slc34a2单克隆抗体及其用途 Pending CN119948054A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/100315 2022-06-22
CN2022100315 2022-06-22
PCT/CN2023/101761 WO2023246879A1 (en) 2022-06-22 2023-06-21 Anti-slc34a2 monoclonal antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN119948054A true CN119948054A (zh) 2025-05-06

Family

ID=89379184

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380053616.2A Pending CN119948054A (zh) 2022-06-22 2023-06-21 抗slc34a2单克隆抗体及其用途

Country Status (13)

Country Link
US (2) US12215150B2 (https=)
EP (1) EP4543926A1 (https=)
JP (1) JP2025520692A (https=)
KR (1) KR20250051643A (https=)
CN (1) CN119948054A (https=)
AU (1) AU2023289743A1 (https=)
CA (1) CA3260354A1 (https=)
CL (1) CL2024004012A1 (https=)
CO (1) CO2024017740A2 (https=)
IL (1) IL317849A (https=)
MX (1) MX2025000053A (https=)
TW (1) TW202409076A (https=)
WO (1) WO2023246879A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120988123A (zh) * 2025-10-21 2025-11-21 苏州近岸蛋白质科技股份有限公司 一种抗人NaPi2b的人源化单克隆抗体及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025131025A1 (en) * 2023-12-21 2025-06-26 Lanova Medicines Development Co., Ltd. Conjugates of anti-slc34a2 antibody and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8603474B2 (en) 2008-01-29 2013-12-10 Ludwig Institute For Cancer Research, Ltd. Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120988123A (zh) * 2025-10-21 2025-11-21 苏州近岸蛋白质科技股份有限公司 一种抗人NaPi2b的人源化单克隆抗体及其应用
CN120988123B (zh) * 2025-10-21 2026-03-17 苏州近岸蛋白质科技股份有限公司 一种抗人NaPi2b的人源化单克隆抗体及其应用

Also Published As

Publication number Publication date
US12215150B2 (en) 2025-02-04
EP4543926A1 (en) 2025-04-30
TW202409076A (zh) 2024-03-01
US20240301052A1 (en) 2024-09-12
AU2023289743A1 (en) 2025-01-09
CL2024004012A1 (es) 2025-05-02
JP2025520692A (ja) 2025-07-03
CO2024017740A2 (es) 2025-05-19
US20250154248A1 (en) 2025-05-15
MX2025000053A (es) 2025-04-02
KR20250051643A (ko) 2025-04-17
CA3260354A1 (en) 2023-12-28
WO2023246879A1 (en) 2023-12-28
IL317849A (en) 2025-02-01

Similar Documents

Publication Publication Date Title
KR102511268B1 (ko) Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용
WO2019241732A1 (en) Blocking antibodies against cd47 and methods of use thereof
CN116745317B (zh) 抗tigit抗体及其用途
US12570742B2 (en) Anti-SIRPα monoclonal antibodies and uses thereof
US12281162B2 (en) Chimeric antigen receptors targeting GPRC5D
WO2022206961A1 (en) Anti-cd24 monoclonal antibodies and uses thereof
US20250154248A1 (en) Anti-slc34a2 monoclonal antibodies and uses thereof
WO2022148370A1 (en) Anti-gprc5d monoclonal antibodies and uses thereof
WO2025131027A1 (en) Anti-slc34a2/anti-4-1bb antibodies and uses thereof
HK40126806A (zh) 抗slc34a2单克隆抗体及其用途
HK40080157A (en) Anti-gprc5d monoclonal antibodies and uses thereof
KR20240150782A (ko) 항-il-13ra2 단클론성 항체 및 그것의 용도
HK40069799A (zh) 抗SIRPα单克隆抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40126806

Country of ref document: HK